Premium
Plasminogen activator inhibitor‐2 (PAI‐2) in eosinophilic leukocytes
Author(s) -
Swartz Jonathan M.,
Byström Jonas,
Dyer Kimberly D.,
Nitto Takeaki,
Wynn Thomas A.,
Rosenberg Helene F.
Publication year - 2004
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.0304182
Subject(s) - eosinophil , biology , plasminogen activator , immunology , eosinophil cationic protein , microbiology and biotechnology , inflammation , major basic protein , endocrinology , asthma
Plasminogen activator inhibitor‐2 (PAI‐2) as a potential eosinophil protein was inferred from our gene microarray study of mouse eosinophilopoiesis. Here, we detect 47 kDa intracellular and ∼60 kDa secretory forms of PAI‐2 in purified human eosinophil extracts. PAI‐2 is present at variable concentrations in eosinophil lysates, ranging from 30 to 444 ng/10 6 cells, with a mean of 182 ng/10 6 cells from 10 normal donors, which is the highest per‐cell concentration among all leukocyte subtypes evaluated. Enzymatic assay confirmed that eosinophil‐derived PAI‐2 is biologically active and inhibits activation of its preferred substrate, urokinase. Immunohistochemical and immunogold staining demonstrated PAI‐2 localization in eosinophil‐specific granules. Immunoreactive PAI‐2 was detected in extracellular deposits in and around the eosinophil‐enriched granuloma tissue encapsulating the parasitic egg in livers of wild‐type mice infected with the helminthic parasite Schistosoma mansoni . Among the possibilities, we consider a role for eosinophil‐derived PAI‐2 in inflammation and remodeling associated with parasitic infection as well as allergic airways disease, respiratory virus infection, and host responses to tumors and metastasis in vivo.